NEW YORK (GenomeWeb News) – OncoMethylome Sciences has inked a worldwide non-exclusive agreement granting Qiagen rights to use certain of its methylation technologies in future Qiagen products, the Liege, Belgium-based firm said today.
The firms anticipate that these future products will expand, among others, Qiagen’s EpiTect product line. Specifically, the agreement covers OncoMethylome Sciences’ methylation-specific PCR technology.
Qiagen will pay OncoMethylome Sciences an upfront fee plus royalties from future product sales utilizing the technology. Additional terms of the pact were not disclosed.
“MSP is a perfect match with our EpiTect product-line and allows us to further enable scientific progress in the development of diagnostics and therapeutics for cancer,” Achim Ribbe, executive director of corporate business development for Qiagen, said in a statement.